KOD
HealthcareKodiak Sciences Inc.
$25.00
$-1.02 (-3.92%)
Jan 5, 2026
Price History (1Y)
Analysis
Kodiak Sciences Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $1.53 billion, it has a significant scale in its industry. The company employs 123 people. The financial health of Kodiak Sciences Inc. reveals a challenging situation, with all profitability metrics at zero percent (gross margin, operating margin, and profit margin). The returns on equity (-207.9%) and assets (-47.2%) are also negative. On the balance sheet side, the company has $72.04 million in cash and $62.20 million in debt, resulting in a debt-to-equity ratio of 262.54. Kodiak Sciences Inc.'s valuation metrics show a P/E ratio of -6.47 and an EV/EBITDA ratio of -6.68, indicating significant losses in the recent past. The forward P/E ratio is also negative (-6.47). There are no dividend payments or payout ratios applicable to this company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Visit website →Key Statistics
- Market Cap
- $1.53B
- P/E Ratio
- N/A
- 52-Week High
- $31.18
- 52-Week Low
- $1.92
- Avg Volume
- 925.63K
- Beta
- 2.67
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 123